NATURE TECHNOLOGY CORPORATION

Company Information
Address 4701 INNOVATION DRIVE
LINCOLN, NE, 68521-


Information

DUNS: 7588486

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Improving Obesity Outcomes Through Interactive Web-Based Clinical Skills Training

    Amount: $247,934.00

    DESCRIPTION (provided by applicant): To commercialize non-viral gene medicines, it is critical that both vector potency (i.e. therapeutic transgene expression levels) and the duration of the therapeut ...

    SBIRPhase I2013Department of Health and Human Services
  2. eukaryotic expression vectors resistant to transgene silencing

    Amount: $920,664.00

    DESCRIPTION (provided by applicant): Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented commercialization of plasmid-based therapies for human health applicat ...

    SBIRPhase II2011Department of Health and Human Services
  3. eukaryotic expression vectors resistant to transgene silencing

    Amount: $145,542.00

    DESCRIPTION (provided by applicant): Eukaryotic expression vectors are utilized for various biomedical applications including protein production, gene therapy and gene vaccination. A key barrier is th ...

    SBIRPhase I2007Department of Health and Human Services
  4. Rapid deployment DNA vaccine for pandemic influenza

    Amount: $207,016.00

    DESCRIPTION (provided by applicant): DNA-only vaccination would significantly enhance the rapid deployment utility of DNA vaccines for pandemic application (development times for DNA vaccines are sign ...

    SBIRPhase I2007Department of Health and Human Services
  5. Chimeric enzyme for nucleic acid autohydrolysis

    Amount: $819,371.00

    DESCRIPTION (provided by applicant): DNA vaccines and gene medicines, derived from bacterial plasmids, are emerging as an important new class of pharmaceuticals. DNA molecules made strictly by rationa ...

    SBIRPhase II2006Department of Health and Human Services
  6. Antisense inhibitors for enhanced plasmid production

    Amount: $136,195.00

    DESCRIPTION (provided by applicant): Large scale manufacture of plasmid DNA is becoming increasingly important as the next generation of biotechnology products (gene medicines and DNA vaccines) make ...

    SBIRPhase I2005Department of Health and Human Services
  7. Chimeric enzyme for host nucleic acid autohydrolysis

    Amount: $143,800.00

    DESCRIPTION (provided by applicant): DNA vaccines and gene medicines are emerging as an important new class of pharmaceuticals that are derived from bacterial plasmids. For use in humans, plasmid D ...

    SBIRPhase I2004Department of Health and Human Services
  8. Promoter Rescue Vectors

    Amount: $142,017.00

    DESCRIPTION (provided by applicant): Mouse VL30 (retrotransposon) long terminal repeats (LTRs) are a potential source of tissue-specific transcriptional promoters that can be used to deliver and expre ...

    SBIRPhase I2003Department of Health and Human Services
  9. GENE SELF ASSEMBLY TECHNOLOGY

    Amount: $139,700.00

    N/A

    SBIRPhase I1998Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government